Details of the Drug Combinations

General Information of This Drug (ID: DMSTH01)

Drug Name

Rocilinostat DMSTH01

Synonyms

1316214-52-4; Rocilinostat (ACY-1215); 2-(Diphenylamino)-N-(7-(hydroxyamino)-7-oxoheptyl)pyrimidine-5-carboxamide; UNII-WKT909C62B; ACY-63; WKT909C62B; 2-(Diphenylamino)-N-[7-(hydroxyamino)-7-oxoheptyl]-5-pyrimidinecarboxamide; AK151416; N-[7-(hydroxyamino)-7-oxoheptyl]-2-(N-phenylanilino)pyrimidine-5-carboxamide; 2-(diphenylamino)-N-[7-(hydroxyamino)-7-oxoheptyl]pyrimidine-5-carboxamide; Ricolinostat [USAN:INN]; AH4; Ricolinostat (USAN/INN); MLS006011181; SCHEMBL574580; GTPL7010

Indication

Disease Entry	ICD 11	Status	REF
Multiple myeloma	2A83	Phase 2	[1]
Autoimmune diabetes	5A10	Phase 1/2	[2]
------------------------------------------------------------------------------------

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

List of Combinatorial Drugs (CBD) Containing This Drug

3 Clinical Trial Drug Combination(s) Consisting of This drug

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
Idelalisib + Rocilinostat	DCXCW67	Idelalisib	Recurrent Chronic Lymphoid Leukemia	[3]
Paclitaxel + Rocilinostat	DCSMG3I	Paclitaxel	Ovarian Cancer	[4]
Rocilinostat + Ibrutinib	DCAWG8H	Ibrutinib	Recurrent Chronic Lymphoid Leukemia	[3]
------------------------------------------------------------------------------------

References

1	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800032606)
2	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7010).
3	ClinicalTrials.gov (NCT02787369) ACY-1215 in Combination With BCR Pathway Inhibitors in Relapsed CLL
4	ClinicalTrials.gov (NCT02661815) A Phase 1b Study of Paclitaxel And Ricolinostat For The Treatment Of Gynecological Cancer